Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 2/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29961829 | 1.00 | PPARG (0.46) | PPARGPPARALTA4HCETPF10 | |
| SCHEMBL11324190 | 0.89 | CYP4F2 (0.50) | PPARGPPARALTA4HCETPFDFT1 | |
| SCHEMBL2351004 | 0.87 | LTA4H (0.53) | LTA4HCETPF10FDFT1TSHR | |
| SCHEMBL29661187 | 0.82 | LTA4H (0.67) | LTA4HTSHRSMN1; SMN2FFAR1FFAR4 | |
| SCHEMBL358425 | 0.82 | LTA4H (0.67) | LTA4HTSHRSMN1; SMN2FFAR1FFAR4 | |
| SCHEMBL30583036 | 0.82 | — | — | |
| SCHEMBL38187 | 0.82 | — | — | |
| SCHEMBL10892547 | 0.82 | CYP4F2 (0.49) | PPARGPPARALTA4HFFAR1FFAR4 | |
| SCHEMBL14656181 | 0.82 | TTR (0.51) | PPARGPPARALTA4HFFAR1FFAR4 | |
| SCHEMBL9560831 | 0.82 | TTR (0.47) | PPARGF10FDFT1TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115368239-B | Synthesis and pharmaceutical application of cinnamate derivative | 南开大学 | 2024-04-26 | — | — | CN | disclosed |
| CN-115368239-A | Synthesis of cinnamate derivative and pharmaceutical application thereof | 南开大学 | 2022-11-22 | — | — | CN | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1688138-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2006-08-09 | — | — | EP | disclosed |
| US-4611009-A | Combating arthropods with 3-phenoxybenzyl 2,2-dimethyl-3-vinylcyclopropane carboxylates | BAYER AKTIENGESELLSCHAFT (DE) | 1986-09-09 | — | — | US | disclosed |
| US-4279920-A | 2,2-Dimethyl-3-(2-bromo-2-phenyl-vinyl)-cyclopropanecarboxylic acid 3-phenoxybenzyl esters and pesticidal use | BAYER AKTIENGESELLSCHAFT (DE) | 1981-07-21 | — | — | US | disclosed |
| US-4276306-A | INSECTICIDES, MITICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1981-06-30 | — | — | US | disclosed |
| EP-0000345-B1 | SUBSTITUTED PHENOXYBENZYLOXYCARBONYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INSECTICIDES AND ACARICIDES | BAYER AG (DE) | 1981-04-01 | — | — | EP | disclosed |
| US-4242357-A | INSECTICIDES, MITICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1980-12-30 | — | — | US | disclosed |
| EP-0019090-A1 | Substituted styryl-cyclopropanecarboxylic acid derivatives, a process for their production, their use, insecticidal and acaricidal compositions, their production and process for combating insects | BAYER AG (DE) | 1980-11-26 | — | — | EP | disclosed |
| EP-0001566-B1 | CYCLOBUTANECARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS INSECTICIDES | BAYER AG (DE) | 1980-11-26 | — | — | EP | disclosed |
| EP-0011695-A1 | Substituted cyclopropane carboxylic acids and their derivatives; their preparation and their use for the preparation of insecticides and acaricides | BAYER AG (DE) | 1980-06-11 | — | — | EP | disclosed |
| EP-0009708-A1 | Substituted m-phenoxy-benzyl bromostyryl-cyclopropane carboxylates (I), processes for their preparation, intermediates obtained thereby and their preparation, compositions containing the esters (I), the use of the esters (I) and methods for the production of insecticidal and/or acaricidal compositions | BAYER AG (DE) | 1980-04-16 | — | — | EP | disclosed |
| EP-0001566-A2 | Cyclobutanecarboxylic acid derivatives, processes for their preparation and their use as insecticides | BAYER AG (DE) | 1979-05-02 | — | — | EP | disclosed |
| EP-0000345-A1 | Substituted phenoxybenzyloxycarbonyl derivatives, their preparation and their use as insecticides and acaricides | BAYER AG (DE) | 1979-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167378-A1 | Receptor Function Regulation Agent | GPR119, INSR, GPR88 | PPARG 210/4885PPARA 283/4885LTA4H 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.